Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

Phase 4 Completed 100 enrolled Baxter Healthcare Corporation Halozyme Therapeutics · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose is to evaluate the ease of use and technical challenges encountered during subcutaneous infusion of Lactated Ringer's (LR) solution, preceded by recombinant human hyaluronidase (hylenex), utilizing commonly used angiocatheter gauges and button delivery systems. The safety and tolerability of hylenex-augmented SC infusion of LR through these delivery systems is also being evaluated.

Timeline

Start: 2008-12
Primary completion: 2009-01
Completion: 2009-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rHuPH20	Protein / enzyme biologic	150 iu	Subcutaneous
Background	Lactated Ringer's solution	Unknown	1000 ml	Subcutaneous

Indications

No indication recorded.